What is LL-37?
LL-37 is the active fragment of human cathelicidin antimicrobial protein, a component of innate immunity found in neutrophils and epithelial surfaces.
Immune & Wellness Support
LL‑37
The only human cathelicidin, studied for antimicrobial defense and its role in tissue repair.
- Format
- 5mg vial — injectable
- Price
- $150 per vial
- Route
- Injectable
- Evidence level
- Preclinical
- Regulatory status
- Compounded
- Testing
- Recent Labs Recommended
Pricing reflects the compounded preparation and doctor review. Final therapy and dosing are determined only after your intake is reviewed.
Overview
Understanding LL-37
Format & administration
Subcutaneous injection over a short course rather than continuously. Your doctor defines duration.
Testing posture
Your doctor determines the final testing requirements for LL-37 after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
How it works
How LL-37 works
- 01Research describes direct membrane activity against a broad range of microbes alongside immunomodulatory signaling and involvement in wound repair — a dual role that distinguishes it from conventional antimicrobials.
Show illustration: LL-37
What has been studied
Potential applications and evidence
These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.
Explored for innate immune support
Discussed within gut and biofilm protocols
Potential support for wound healing
Typically used as a short, defined course
Doctor-guided
A personalized approach
Your doctor determines the final testing requirements for LL-37 after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
Bloodwork status: Recent Labs Recommended
Commonly reviewed at baseline
- CBC with differential
- Comprehensive metabolic panel (CMP)
- hs-CRP
Follow-up & monitoring
CBC and inflammatory markers are commonly rechecked at 8 to 12 weeks when they were abnormal at baseline.
Medication review
Your doctor reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.
Format & dosing
Subcutaneous injection over a short course rather than continuously. Your doctor defines duration.
Safety
What patients should know
- Compounded, not FDA-approved. Inflammatory flare responses are reported; patients with autoimmune conditions require careful review.
Who may not be a candidate
- Pregnancy or nursing
- Active malignancy without oncology clearance
- Known hypersensitivity to the preparation
- Autoimmune disease without specialist co-management
Regulatory status: Compounded. Evidence level: Preclinical. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed doctor after review of your history.
Common questions
Frequently asked questions
Keep exploring
Related therapies
Ready when you are
Find out what your body is actually asking for.
Fill out a short intake form and our care team will build a plan grounded in your labs — not a guess from a supplement aisle.